Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.

Ruiz ES, Muñoz-Couselo E, Montaudié H, Berciano-Guerrero MA, de la Gala MDCÁ, Charles J, Quéreux G, Nardin C, Tur RY, Dalle S, Beylot-Barry M, Ladwa R, McGrath M, Brungs D, Harris D, Shue H, Tazbirkova A, Fourie S, Malan DR, Oliviero J, Wilcoxen LN, Gray WG, Clingan P.

Open source

DOI: 10.1016/j.jaad.2025.09.009
Published: 2025-09-29
Container: J Am Acad Dermatol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jaad.2025.09.009,
  title = {Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.},
  author = {Ruiz ES and  Muñoz-Couselo E and  Montaudié H and  Berciano-Guerrero MA and  de la Gala MDCÁ and  Charles J and  Quéreux G and  Nardin C and  Tur RY and  Dalle S and  Beylot-Barry M and  Ladwa R and  McGrath M and  Brungs D and  Harris D and  Shue H and  Tazbirkova A and  Fourie S and  Malan DR and  Oliviero J and  Wilcoxen LN and  Gray WG and  Clingan P.},
  year = {2026},
  journal = {J Am Acad Dermatol},
  doi = {10.1016/j.jaad.2025.09.009},
  url = {https://doi.org/10.1016/j.jaad.2025.09.009}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.
AU  - Ruiz ES
AU  -  Muñoz-Couselo E
AU  -  Montaudié H
AU  -  Berciano-Guerrero MA
AU  -  de la Gala MDCÁ
AU  -  Charles J
AU  -  Quéreux G
AU  -  Nardin C
AU  -  Tur RY
AU  -  Dalle S
AU  -  Beylot-Barry M
AU  -  Ladwa R
AU  -  McGrath M
AU  -  Brungs D
AU  -  Harris D
AU  -  Shue H
AU  -  Tazbirkova A
AU  -  Fourie S
AU  -  Malan DR
AU  -  Oliviero J
AU  -  Wilcoxen LN
AU  -  Gray WG
AU  -  Clingan P.
PY  - 2026
JO  - J Am Acad Dermatol
DO  - 10.1016/j.jaad.2025.09.009
UR  - https://doi.org/10.1016/j.jaad.2025.09.009
ER  -

APA

ES, R., E, M., H, M., MA, B., MDCÁ, D. L. G., J, C., G, Q., C, N., RY, T., S, D., M, B., R, L., M, M., D, B., D, H., H, S., A, T., S, F., DR, M., J, O., LN, W., WG, G., & P., C. (2026). Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2025.09.009

Source records

europe-pmc · retrieved 2026-09-25T21:38:47.157Z
hal · retrieved 2026-09-25T21:38:47.198Z